[PDF][PDF] PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

CL Corless, A Schroeder, D Griffith… - Journal of clinical …, 2005 - researchgate.net
CL Corless, A Schroeder, D Griffith, A Town, L McGreevey, P Harrell, S Shiraga…
Journal of clinical oncology, 2005researchgate.net
Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of
the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs,
however, contains mutations in the homologous kinase platelet derived growth factor
receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib
in vitro. Little is known of the other types of PDGFRA mutations that occur in GISTs.
Purpose
Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Little is known of the other types of PDGFRA mutations that occur in GISTs.
researchgate.net